{
    "organizations": [],
    "uuid": "d2e4e580f69fba28ffad42def1c49132741ddcd4",
    "author": "",
    "url": "https://www.reuters.com/article/brief-abbvie-submits-marketing-authoriza/brief-abbvie-submits-marketing-authorization-application-to-ema-for-investigational-treatment-risankizumab-for-moderate-to-severe-plaque-psoriasis-idUSFWN1S8094",
    "ord_in_thread": 0,
    "title": "BRIEF-Abbvie Submits Marketing Authorization Application To EMA For Investigational Treatment Risankizumab For Moderate To Severe Plaque Psoriasis",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 1, 2018 / 12:51 PM / Updated 11 minutes ago BRIEF-Abbvie Submits Marketing Authorization Application To EMA For Investigational Treatment Risankizumab For Moderate To Severe Plaque Psoriasis Reuters Staff 1 Min Read\nMay 1 (Reuters) - AbbVie Inc:\n* ABBVIE SUBMITS MARKETING AUTHORIZATION APPLICATION TO THE EUROPEAN MEDICINES AGENCY FOR INVESTIGATIONAL TREATMENT RISANKIZUMAB FOR MODERATE TO SEVERE PLAQUE PSORIASIS\n* ABBVIE INC - APPLICATION SUPPORTED BY FOUR PIVOTAL PHASE 3 TRIALS EVALUATING MORE THAN 2,000 PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS Source text for Eikon: Further company coverage:",
    "published": "2018-05-01T15:49:00.000+03:00",
    "crawled": "2018-05-01T16:05:36.004+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "pm",
        "updated",
        "minute",
        "ago",
        "submits",
        "marketing",
        "authorization",
        "application",
        "ema",
        "investigational",
        "treatment",
        "risankizumab",
        "moderate",
        "severe",
        "plaque",
        "psoriasis",
        "reuters",
        "staff",
        "min",
        "read",
        "may",
        "reuters",
        "abbvie",
        "inc",
        "abbvie",
        "submits",
        "marketing",
        "authorization",
        "application",
        "european",
        "medicine",
        "agency",
        "investigational",
        "treatment",
        "risankizumab",
        "moderate",
        "severe",
        "plaque",
        "psoriasis",
        "abbvie",
        "inc",
        "application",
        "supported",
        "four",
        "pivotal",
        "phase",
        "trial",
        "evaluating",
        "patient",
        "moderate",
        "severe",
        "plaque",
        "psoriasis",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}